International expansion remains one of the key growth strategies for companies in the life sciences sector. In particular, the United States represents one of the most attractive markets for pharmaceutical, biotechnology, and medical device companies due to its capacity for innovation, market size, and investment environment. However, entering this market also involves significant tax challenges that must be considered from the earliest stages of planning, especially with regard to Transfer Pricing.
The Strategic Role of Intangible Assets
Unlike other economic sectors, life sciences companies typically generate a large portion of their value through intangible assets. Patents, proprietary technologies, research and development outcomes, clinical data, pharmaceutical formulas, and specialized knowledge are fundamental elements of their business models. As a result, related-party transactions involving these assets often become a primary focus for tax authorities.
The economic importance of these intangibles requires multinational companies to carefully analyze how relationships between group entities are structured and what roles each entity plays in the creation and exploitation of these assets.
Intragroup Transactions and Compliance with the Arm’s Length Principle
When a company establishes operations in the United States, it is common for various transactions to occur between entities within the same corporate group. Licensing of intellectual property, the provision of specialized services, intragroup financing, or shared research and development activities are common examples of transactions that must be analyzed under Transfer Pricing rules.
In these cases, it is essential to demonstrate that the terms agreed upon between related parties are consistent with those that would have been agreed upon between independent companies under comparable circumstances. This analysis takes on particular importance when transactions involve unique or high-value-added assets.
The U.S. Regulatory Perspective
In the United States, Section 482 of the Internal Revenue Code grants the Internal Revenue Service (IRS) broad authority to review and adjust the economic terms of transactions between related companies when it determines that these do not reflect the arm’s-length principle.
The objective of this regulation is to ensure that revenues and expenses are properly allocated among related entities, preventing profits from being artificially shifted to jurisdictions with a lower tax burden. As a result, related-party transactions involving intangibles often receive special attention during tax audits.
Value Creation and the Allocation of Profits Associated with Intangibles
The growing importance of intangible assets has led to increased scrutiny by tax authorities regarding how multinational groups allocate the profits derived from their exploitation. In highly innovative industries such as Life Sciences, it is becoming increasingly important to demonstrate which entities are effectively involved in the research, development, improvement, and commercialization of the assets that generate value within the group.
While the OECD Transfer Pricing Guidelines incorporate the DEMPE concept as a tool for analyzing the economic contribution of the various entities involved in the creation and exploitation of intangibles, U.S. regulations are primarily based on Section 482 of the Internal Revenue Code and its associated regulations. However, both the OECD’s and the IRS’s approaches seek to ensure that the allocation of profits adequately reflects the functions performed, the risks assumed, and the assets used by each participating entity.
In this context, multinational companies must carefully assess the economic substance of their operations and the actual contribution of each entity within the value chain, especially when high-value-economic intangible assets are involved.
Valuation Challenges in the Industry
The proper valuation of intangible assets represents one of the greatest challenges for companies in the life sciences sector. The uniqueness of many technologies, the lack of reliable comparables, and the uncertainty inherent in research and development projects can significantly complicate the determination of market prices.
Furthermore, innovation processes typically require substantial investments and long development periods—factors that increase the complexity of the economic analyses used to support Transfer Pricing policies.
The Importance of Technical Documentation
In this context, transfer pricing documentation takes on strategic importance. Having technically sound studies in place helps support the pricing policy applied by the corporate group, demonstrate compliance with the arm’s-length principle, and reduce exposure to potential tax adjustments.
Furthermore, adequate documentation helps mitigate the risk of double taxation, facilitates compliance with requests from tax authorities, and strengthens the taxpayer’s position in the event of tax audits.
As tax authorities strengthen their enforcement mechanisms and increase the exchange of information between jurisdictions, life sciences companies face the need to incorporate Transfer Pricing as an essential component of their international expansion strategy.
Proper management of intangible assets, analysis of value-generating functions, and the implementation of policies aligned with international standards are fundamental elements for reducing tax risks and promoting sustainable growth in highly competitive markets such as the U.S. market.
At TPC Group, we have a team specializing in Transfer Pricing and international taxation that advises multinational companies on the valuation of intangible assets, the design of intra-group policies, and compliance with the documentation requirements of various jurisdictions. Our approach combines technical expertise and industry knowledge to help organizations manage their tax risks and strengthen their global expansion strategies.
Source: